Clinical trials: Glioblastoma (GBM), active
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
- Trial name
- NCT07326566
- Testing
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Where
- 35 sites in United States
- Volunteers
- 162 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Glioblastoma (GBM), High Grade Gliomas
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent…
- Conditions
- Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
- Trial name
- ADePT (NCT07346144)
- Testing
- TGX-007, Valaciclovir
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Trogenix ltd
Glioblastoma (GBM), Astrocytoma, Grade IV
UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4
This study builds on the results of prior studies (UNITED and UNITED-3). The goal of UNITED-4 is to test whether an adaptive radiation therapy (RT) therapy approach ('dose painting'), with reduced margins, impacts approach in…
- Trial name
- UNITED-4 (NCT07459101)
- Testing
- Dose painting + Reduced Margins
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Sunnybrook Health Sciences Centre
Glioblastoma, GBM
Surgical Nivolumab And Ipilimumab For Recurrent GBM
This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.
- Conditions
- Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
- Trial name
- NCT04606316
- Testing
- Nivolumab, Ipilimumab, Surgery
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Gilbert Youssef
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal.
- Conditions
- Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor
- Trial name
- NCT07416188
- Testing
- LMP744, Conventional Surgery or Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastom WHO Grade 4, GBM
TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma
This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain)…
- Conditions
- Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM
- Trial name
- CV01-104 (NCT07862647)
- Testing
- 5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alpheus Medical, Inc.
Glioblastoma, Recurrent Glioblastoma
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls.
- Conditions
- Glioblastoma, Recurrent Glioblastoma, GBM
- Trial name
- SONOBIRD (NCT05902169)
- Testing
- SonoCloud-9 (SC9), Carboplatin, Lomustine
- Where
- 56 sites in United States, Austria and 9 more
- Volunteers
- 560 people
- Sponsor
- CarThera
Glioma, Glioblastoma (GBM)
Pilot IntraOperative Neuronal Electrophysiology in Tumor rElatEd suRgery
INTRODUCTION AND RATIONALE Aggressive brain tumors like glioma have the ability to infiltrate the surrounding healthy brain tissue, disrupting normal neuronal activities and leading to impaired motor and cognitive functions, as…
- Conditions
- Glioma, Glioblastoma (GBM), Brain Tumor-Glioma, Brain Metastasis
- Trial name
- PIONEER (NCT06617208)
- Testing
- Neuropixel probe recording
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Glioma, Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.
- Conditions
- Glioma, Glioblastoma, GBM, Glioma, Malignant
- Trial name
- ENDURANCE (NCT07821112)
- Testing
- GammaTile®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Advanced Solid Tumors, Solid Tumor
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
- Conditions
- Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult
- Trial name
- NCT02974738
- Testing
- Belzutifan
- Volunteers
- 120 people
- Sponsor
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Primary Malignant Brain Tumor, Glioblastoma (GBM)
FearLess in NeuroOncology
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant…
- Conditions
- Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma
- Trial name
- NCT06989086
- Testing
- Fearless in Neuro-Oncology
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Virginia Commonwealth University
Brain Tumors and/or Solid Tumors Including, Glioblastoma
Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach
Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management.
- Conditions
- Brain Tumors and/or Solid Tumors Including, Glioblastoma, Glioblastoma (GBM), Glioblastoma - Category
- Trial name
- FLUO-LB (NCT07420543)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Glioblastoma (GBM)
Mental Health and Suicidality in Glioblastoma Patients in Germany
The aim of the study is to use standardized questionnaires to systematically record influencing factors or predictors for suicidal behavior in glioblastoma patients, particularly with regard to existing depression and anxiety…
- Trial name
- SHINE-GLIO (NCT07409584)
- Testing
- Medical history, physical examination, completing questionnaires, data collection
- Where
- 6 sites in Germany
- Volunteers
- 180 people
- Sponsor
- University Hospital, Essen
MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
This clinical trial is designed with two treatment stages: Stage 1: one cycle of study drug treatment prior to initiation of first-line standard radiation in all study participants.
- Trial name
- NCT07778602
- Testing
- avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma (GBM)
BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
This is an open-label, multi-center, Phase 0/2 trial designed to enroll up to 78 total participants with suspected newly diagnosed glioblastoma (nGBM) who are scheduled for surgical resection to accrue at least 14 participants in…
- Trial name
- NCT07485049
- Testing
- BGB-58067
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Nader Sanai
Glioblastoma (GBM)
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
The objective of this study is to evaluate the safety, feasibility, and preliminary antitumor activity of this multi-component immunotherapy strategy in patients with advanced solid tumors.
- Trial name
- NCT07762716
- Testing
- BreakVax, Ipilimumab 2.5 mg, Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- BreakBio Corp
Glioblastoma (GBM)
Hypoxia-targeted Radiotherapy Boost for GBM
The purpose of this study is to evaluate the use of dynamic contrast-enhanced MRI (DSC-MRI) to identify and target hypoxic tumor regions in glioblastoma (GBM).
- Trial name
- NCT07769918
- Testing
- Dynamic susceptibility contrast MRI (DSC-MRI), Cercare Medical Neurosuite (CMN) DSC-MRI-derived hypoxia maps, Varian TrueBeam
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma)
5G-EMERALD: Amivantamab in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of amivantamab and to determine the preliminary antitumour activity of amivantamab administered at the recommended Phase 2 dose (RP2D).
- Conditions
- Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM)
- Trial name
- 5G-EMERALD (NCT06632236)
- Testing
- Amivantamab
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Glioblastoma, Glioblastoma (GBM)
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when administered twice into the brain where the tumor is located. This is a Phase IB 2 dosing study.
- Conditions
- Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III
- Trial name
- NCT06614855
- Testing
- C134
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- James Markert, MD